1 / 23

Introduction Motivation and Hypothesis

Prescription Drug Demand Based on Mortality Carter Cothran Thesis Presentation for Master of Arts in Economics July 13, 2005. Introduction Motivation and Hypothesis. What determines drug prices? Are they priced efficiently?

shaw
Télécharger la présentation

Introduction Motivation and Hypothesis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prescription Drug Demand Based on MortalityCarter CothranThesis Presentation for Master of Arts in EconomicsJuly 13, 2005 Cothran: Drug Pricing

  2. IntroductionMotivation and Hypothesis • What determines drug prices? Are they priced efficiently? • Will the price of a prescription drug be influenced by the number of deaths or productivity losses it potentially avoids, in addition to other competitive influences? • Estimate price as a function of market competition and the harm caused by the disease it treats. Cothran: Drug Pricing

  3. Previous Literature • Danzon and Chao: “Does Regulation Drive out Competition in Pharmaceutical Markets?” JLE, 2000. • Study effects of regulation on drug prices across 7 countries. • Find that U.S. has greater effects of competition on prices through large generic market and first-mover advantage. Cothran: Drug Pricing

  4. PreviousLiterature - 2 • Civan and Maloney: Working paper, 2004. Evidence that drug development is motivated by incidence of disease and resulting economic loss. • But, only for U.S. and a few other developed countries. • Inefficient Pricing? Cothran: Drug Pricing

  5. Data Collection and Organization Sample of Drugs • List of top sales and top prescriptions written for 2003 & 2004 • Rankings from Rxlist.com. • Omitted drugs that were obviously not associated with fatal illnesses. • Therapeutic competitors, pioneer brands, & ingredient equivalents (imitators) for these drugs were added to the collection if not already listed. Cothran: Drug Pricing

  6. Data Collection and Organization Prices • Medco.com • Retail prices: average of 60,000 pharmacies • Formulary: price from state insurance plan • Information with price: • strength • package size or quantity • type, generic or brand • manufacturer of brand Cothran: Drug Pricing

  7. Data Collection and Organization - 2Treatments, Dates, and Death totals • Indications & Approval Dates: Rxlist.com, FDA label, Nursing Drug Handbook • Also used to categorize which drugs are competitors. • Mortality Data: CDC (1999 death tables) • Link between categories of mortality and indications; sometimes loose and sometimes very specific. Cothran: Drug Pricing

  8. Empirical AnalysisVariables • Price: average of price per amount of active ingredient in standard prescription. • Variance of this price per unit of ingredient is informative. • Sometimes forms can be combined; sometimes not. Average price over forms. Cothran: Drug Pricing

  9. Empirical Analysis – 2Variables • Discount: Retail price minus formulary price divided by formulary price. • Age: time since approval date • First dates • Classes of Drugs: On Patent; Pioneer; Imitator • Tables 1, 2, and 3: Summary Statistics Cothran: Drug Pricing

  10. Cothran: Drug Pricing

  11. Cothran: Drug Pricing

  12. Cothran: Drug Pricing

  13. Determinants of Price • Table 4: Regression using determinants from own-price effects • Examine differences among 3 types of drugs, On Patent, Pioneer, and Imitator (omitted category) • Not enough information for competitive influences Cothran: Drug Pricing

  14. Cothran: Drug Pricing

  15. Measuring Competitive EffectsVariables • Therapeutic Competitor Categories • Disease treated • Action that drug takes • Table 5: Frequency Table of Therapeutic Competitor Categories • 121 categories • Number of drugs in each Cothran: Drug Pricing

  16. Cothran: Drug Pricing

  17. Effects of Competition • Competitor price measured by: • Average price in Therapeutic Competitor Category • Average price of Ingred. Equivalents for Pioneer; Therapeutic Competitor Category for On Patent • Fixed Effects model to capture avg price in Therapeutic Competitor Categories Cothran: Drug Pricing

  18. Cothran: Drug Pricing

  19. Mortality Effects • Linking Mortality to Therapeutic Competitor Categories • Table 7: Summary Statistics • General and Specific Category Deaths • Death Rate: divide by total 1999 deaths • Alternative General Category: equals specific category deaths when general deaths are same as specific deaths. • Fixed Effects Values: results from regression (c ) in Table 6 Cothran: Drug Pricing

  20. Cothran: Drug Pricing

  21. Relating Mortality to Price • Table 8: Regression of Death Totals on Relative Prices for Therapeutic Competitor Categories • Regressions a-d use F. E. coefficient values • Regressions d-e use F. E. t-statistic values Cothran: Drug Pricing

  22. Cothran: Drug Pricing

  23. Conclusions • Results offer support for using mortality as a measure of demand intensity. • Additional work: • Add more drugs (make sure that sample includes imitators if available) • Refine therapeutic categories • Refine links between therapeutic categories & mortality Cothran: Drug Pricing

More Related